BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

OnKure Therapeutics updates on PIKture-01 trial progress, financial results, and expansion of PI3Ka programs, with milestones expected through 2026. OnKure Therapeutics provided an update on its ...

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; ...

With its lead asset RLY-2608, a PI3Ka inhibitor showing promising results in breast cancer trials, and a recent strategic acquisition, Relay is positioning itself as a potential leader in targeted ...

OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

Cash and cash equivalents were approximately $110.8 million as of December 31, 2024. “I am extremely pleased with the progress we made last ...

“I am extremely pleased with the progress we made last year. With three PI3Ka inhibitor programs, including one in clinical development and a second development candidate expected next ...

Relay Therapeutics specializes in developing targeted therapies for cancer patients, with a particular emphasis on precision medicines. The company’s flagship product, RLY-2608, is a PI3Ka ...

Relay Therapeutics specializes in developing targeted therapies for cancer patients, with a particular emphasis on precision medicines. The company’s flagship product, RLY-2608, is a PI3Ka inhibitor ...